Trial Profile

A Phase I Trial of the Alpha Particle-emitting Radiopharmaceutical, Af-001, in Patients With Differentiated Thyroid Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Af 001 (Primary)
Indications Thyroid cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Alpha Fusion

Most Recent Events

27 Nov 2025 New trial record
31 Oct 2025 According to Alpha Fusion media release, this clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka.
31 Oct 2025 According to an Alpha Fusion media release, Part Ia of the study will be conducted at the National Cancer Center Hospital East (Principal Investigator: Dr. Makoto Tahara, Chief, Department of Head and Neck Medical Oncology), and Part Ib will be conducted at multiple sites in Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com